G-C 15 Childhood liver oncology c-LOG
The Childhood Liver Oncology Group (c-LOG) is a research group that forms part of the Gastroenterology department of the Hospital Germans Trias i Pujol (HUGTP), it is also part of the Biomedical Research Networking Centre (CIBER) for Liver and Digestive diseases of the Spanish Health Research Institute (Instituto Carlos III). The group is included in the Program for Predictive and Personalized Cancer at the IGTP (PMPPC-IGTP).
The cLOG is also supported by the Spanish Society of Paediatric Haematology and Oncology (SEHOP) and the Childhood Liver Tumours Strategy Group (SIOPEL), the European group for the Study of Paediatric Liver Tumours.
The c-LOG group is led by Carolina Armengol, PhD.
The group was created in 2010 with the aim of increasing translational research into paediatric liver tumours, a rare disease with an incidence of 1-1.5 children diagnosed per million children per year. To do this, we contributed to the creation of a multidisciplinary Spanish Group for the Study of Paediatric Liver tumours (GEETHI) that includes paediatric oncologists, surgeons, pathologists and basic researchers from the main Spanish paediatric hospitals: H. Reina Sofia of Córdoba, H. La Paz and Gregorio Marañón of Madrid; H. Vall d'Hebron of Barcelona and IGTP.
Molecular studies of childhood liver cancer have been hampered by the rarity of the disease. One of the main tasks of the c-LOG was to establish a collection of biospecimens from patients with which to support our research. With this objective, we created the Childhood Liver Cancer Network (CLCN) collection in 2010 at national level and currently, it is extending to other European countries.
Subsequently, the group was awarded with a H2020 research grant and joined the ChiLTERN Project, a European research project funded by the Horizon 2020 Programme. ChiLTERN will not only extend the collection of samples from patients across Europe, but will also run the single largest paediatric clinical trial. The programme aims to cure more children with liver cancer and expose fewer children to toxic chemotherapy.
Childhood Liver Cancer
Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the predominant malignant liver cancers in early and late childhood, respectively. Despite great advances during recent decades, which have improved disease outcome for patients with HB using chemotherapy and surgical approaches, there are very limited treatment options for 10-20% of patients who suffer from immature and metastatic tumours. Importantly, cancer survivors can suffer serious side effects. In contrast to HB, HCC has a worse prognosis and the unique realistic chance of cure for HCC is an early diagnosis.
The cLOG research lines based on the investigation of collected tumours are focussed on increasing molecular knowledge of the underlying mechanisms responsible for hepatocarcinogenesis and tumour progression. We use the latest "omics" technologies in order to identify diagnostic/prognostic biomarkers and key molecular pathways for improving the clinical management and treatment of children suffering of liver cancer.
- Establishment of the Childhood Liver Cancer Network (CLCN) collection
This is a centralized and prospective collection of biological samples from pediatric patients with liver cancer that was created in 2010 at the IGTP thanks to the development of a multidisciplinary network with the main pediatric hospitals of Spain. Currently, the CLCN collection includes more than 100 high quality biospecimens (plasma, DNA and tissue) obtained from about 60-70% of the patients diagnosed in Spain. This biorepository is sponsored by the Germans Trias i Pujol Health Research Institute (IGTP) and is now included in the ChiLTERN project
This project, which recently received a European H2020 grant, will allow us, as WP3 leaders, to extend the CLCN collection to other European countries thanks to their integration into the Paediatric Hepatic International Tumour Trial (PHITT). This collection will allow us to (i) identify highly validated panels of diagnostic and prognostic biomarkers in both HB and HCC and (ii) determine if paediatric HCC is a biologically different entity to adult HCC.
Follow ChiLTERN on Twitter @chilterncollab
- Proteomic study of Hepatoblastoma: Identification of a 3-protein signature to improve clinical stratification of childhood liver cancer and key deregulated pathways
This study has been carried out in collaboration with Dr. F Elortza of the Proteomic platform of the CICBioGUNE (Bilbao, Spain) and is the first proteomic study with hepatoblastoma samples. Proteomic studies are continuing within the Workpackage 3 of the ChiLTERN Project.
- Molecular characterization of childhood liver cancer by integrating RNA-sequencing, genomic and transcriptomic data.
This project is conducted in collaboration with Dr. JM Llovet (Icahn School of Medicine at Mount Sinai, New York), Dr. Francesc Solé of the the Josep Carreras Research Institute (Can Ruti Campus, Badalona) and the Microarray Analysis Service (IMIM, Barcelona).
- Plasma proteomic profiling of adult patients with different degree of liver damage: identification of biomarkers of hepatocellular carcinoma.
This is a amulticentre study with 6 different Spanish hospitals participating: (HUGTiP, Badalona; H. Josep Trueta, Girona; H. del Mar, Barcelona; Parc Taulí, Sabadell; H. Puerta de Hierro, Madrid; H. Universitario Central de Asturias). It has allowed the establishment of a biological samples collection (plasma and tissue samples) from 560 adult patients with different degrees of liver damage. The project is also conducted in collaboration with Dr. JM Estanyol and O. Bachs of the Proteomic platform and the Cellular Biology department of the Barcelona University respectively.
(+34) 93 497 86 88